专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050256170A1 EP2 receptor agonists 失效
公开(公告)号：US20050256170A1
公开(公告)日：2005-11-17
申请号：US11055724
申请日：2005-02-11
申请人： Alexander Oxford , Richard Davis , Robert Coleman , Kenneth Clark , David Clark , Neil Harris , Garry Fenton , George Hynd , Keith Stuttle , Jonathan Sutton , Mark Ashton , Edward Boyd , Shirley Brunton
发明人： Alexander Oxford , Richard Davis , Robert Coleman , Kenneth Clark , David Clark , Neil Harris , Garry Fenton , George Hynd , Keith Stuttle , Jonathan Sutton , Mark Ashton , Edward Boyd , Shirley Brunton
IPC分类号： A61K31/4178 , A61K31/422 , A61K31/427 , A61K31/4439 , C07C233/75 , C07C233/81 , C07C235/84 , C07D213/81 , C07D233/90 , C07D257/04 , C07D277/24 , C07D277/26 , C07D277/56 , C07D307/46 , C07D307/68 , C07D307/91 , C07D333/38 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/12 , C07D413/02 , C07D417/02 , C07D43/02
CPC分类号： C07D213/81 , C07C233/75 , C07C233/81 , C07C235/84 , C07D233/90 , C07D257/04 , C07D277/24 , C07D277/26 , C07D277/56 , C07D307/46 , C07D307/68 , C07D307/91 , C07D333/38 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/12
摘要： A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein: R5is an optionally substituted C5-20 aryl or C4-20 alkyl group; A is selected from the group consisting of: wherein X and Y are selected from the group consisiting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O., and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; R3 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R4 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R6 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; D is selected from: B is selected from the group consisting of: where RN′ is selected from H and C1-4 alkyl; where one of RP3 and RP4 is —Cm alkylene-R2 and the other of RP3 and RP4 is H, m and n can be 0 or 1, and m+n=1 or 2; and additionally when RP3 is —Cm alkylene-R2, m can also be 2 or 3, and m+n=1, 2, 3 or 4, and when R2 is tetrazol-5-yl, m+n may be 0; or where one of RP3 and RP4 is —O—CH2—R2, and the other of RP3 and RP4 is H, n is 0; RN is H or optionally substituted C1-4 alkyl; R2 is either: —CO2H (carboxy); —CONH2; —CH2-OH; or tetrazol-5-yl.

2. 发明申请

US20070123575A1 EP4 RECEPTOR ANTAGONISTS 失效
标题翻译： EP4受体拮抗剂
公开(公告)号：US20070123575A1
公开(公告)日：2007-05-31
申请号：US11615024
申请日：2006-12-22
申请人： Alexander Oxford , Richard Davis , Robert Coleman , Kenneth Clark , David Clark , Neil Harris , Garry Fenton , George Hynd , Keith Stuttle , Jonathan Sutton , Christopher Newton
发明人： Alexander Oxford , Richard Davis , Robert Coleman , Kenneth Clark , David Clark , Neil Harris , Garry Fenton , George Hynd , Keith Stuttle , Jonathan Sutton , Christopher Newton
IPC分类号： A61K31/41 , A61K31/34 , C07D405/02
CPC分类号： C07D307/54 , A61K31/34 , A61K31/341 , A61K31/4155 , A61K31/443 , C07D307/64 , C07D307/68 , C07D405/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14
摘要： Compounds of formula (I): wherein: R2 is H or an optionally substituted C1-4 alkyl group; Y is either —(CH2)n—X—, where n is 1 or 2 and X is O, S, S(═O), S(═O)2, or NRN1, where RN1 is selected from H or optionally substituted C1-4 alkyl, or Y is —C(═O)NRN2—, where RN2 is selected from H, and optionally substituted C1-7 alkyl or C5-20 aryl; R3 is an optionally substituted C6 aryl group linked to a further optionally substituted C6 aryl group, wherein if both C6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C1-3 alkylene group; and R5 is either: (i) carboxy; (ii) a group of formula (II): ; or (iii) a group of formula (III): wherein R is optionally substituted C1-7 alkyl, C5-20 aryl or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl; (iv) tetrazol-5-yl.
摘要翻译：式（I）的化合物：其中：R 2是H或任选取代的C 1-4烷基; Y是 - （CH 2）n -X-，其中n是1或2，X是O，S，S（-O），S（-O ）N 2，或NR 11，其中R 0,1选自H或任选取代的C 1-4烷基，或Y是-C（-O）NR N2 - ，其中R N2选自H和任选取代的C 1-7 - 烷基或C 5-20-20芳基; R 3是与另外任选取代的C 6 -C 6芳基连接的任选取代的C 6-14芳基，其中如果两个C 6 芳基是苯环，两个环之间可能有一个氧桥，与两个环上的连接相邻; A是单键或C 1-3-3亚烷基; 和R 5是：（i）羧基; （ii）式（II）的组：或（iii）式（III）的基团：其中R是任选取代的C 1-7烷基，C 5-20-20芳基或NR N 3，其中R“N 3”和“R”N 4“独立地选自任选取代的C 1-4烷基 ; （ⅳ）四唑-5-基。

3. 发明申请

US20080039502A1 EP4 receptor antagonists 失效
标题翻译： EP4受体拮抗剂
公开(公告)号：US20080039502A1
公开(公告)日：2008-02-14
申请号：US11889570
申请日：2007-08-14
申请人： Alexander Oxford , Richard Davis , Robert Coleman , Kenneth Clark , David Clark , Neil Harris , Garry Fenton , George Hynd , Keith Stuttle , Jonathan Sutton , Christopher Newton
发明人： Alexander Oxford , Richard Davis , Robert Coleman , Kenneth Clark , David Clark , Neil Harris , Garry Fenton , George Hynd , Keith Stuttle , Jonathan Sutton , Christopher Newton
IPC分类号： A61K31/34 , A61K31/341 , A61K31/4155 , A61K31/443 , A61P25/06 , C07D231/12 , C07D231/18 , C07D307/68 , C07D307/77 , C07D405/12 , C07D413/12
CPC分类号： C07D307/54 , A61K31/34 , A61K31/341 , A61K31/4155 , A61K31/443 , C07D307/64 , C07D307/68 , C07D405/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14
摘要： Compounds of formula (I): wherein: R2 is H or an optionally substituted C1-4 alkyl group; Y is either —(CH2)n—X—, where n is 1 or 2 and X is O, S, S(═O), S(═O)2, or NRN1, where RN1 is selected from H or optionally substituted C1-4 alkyl, or Y is —C(═O)NRN2—, where RN2 is selected from H, and optionally substituted C1-7 alkyl or C5-20 aryl; R3 is an optionally substituted C6 aryl group linked to a further optionally substituted C6 aryl group, wherein if both C6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C1-3 alkylene group; and R5 is either: (i) carboxy; (ii) a group of formula (II): (iii) a group of formula (III): wherein R is optionally substituted C1-7 alkyl, C5-20 aryl or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl; (iv) tetrazol-5-yl.
摘要翻译：式（I）的化合物：其中：R 2是H或任选取代的C 1-4烷基; Y是 - （CH 2）n -X-，其中n是1或2，X是O，S，S（-O），S（-O ）N 2，或NR 11，其中R 0,1选自H或任选取代的C 1-4烷基，或Y是-C（-O）NR N2 - ，其中R N2选自H和任选取代的C 1-7 - 烷基或C 5-20-20芳基; R 3是与另外任选取代的C 6 -C 6芳基连接的任选取代的C 6-14芳基，其中如果两个C 6 芳基是苯环，两个环之间可能有一个氧桥，与两个环上的连接相邻; A是单键或C 1-3-3亚烷基; 和R 5是：（i）羧基; （ii）式（II）的基团：（iii）式（III）的基团：其中R是任选取代的C 1-7烷基，C 5〜20 其中R“N 3”和“R”N 4“独立地选自任选取代的C 1 -C 6烷基，烷基; （ⅳ）四唑-5-基。

4. 发明申请

US20070135503A1 Furan derivatives as ep4 receptor antagonists 失效
标题翻译：呋喃衍生物作为ep4受体拮抗剂
公开(公告)号：US20070135503A1
公开(公告)日：2007-06-14
申请号：US10576095
申请日：2004-10-15
申请人： David Clark , Neil Harris , Garry Fenton , George Hynd , Keith Stuttle , Jonathan Sutton , Alexander Oxford , Richard Davis , Robert Coleman , Kenneth Clark
发明人： David Clark , Neil Harris , Garry Fenton , George Hynd , Keith Stuttle , Jonathan Sutton , Alexander Oxford , Richard Davis , Robert Coleman , Kenneth Clark
IPC分类号： A61K31/41 , A61K31/34 , A61K31/405 , C07D307/02
CPC分类号： C07D307/68
摘要： A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein one of R2 and R5 is: (i) H or an optionally substituted C1-4 alkyl group; or (ii) an optionally substituted C5-7 aryl; and the other of R2 and R5 is the other group; m and n can be 0 or 1, and m+n=1 or 2 RN is H or optionally substituted C1-4 alkyl R3 is either: (i) carboxy; (ii) a group of formula (II): (iii) a group of formula (III): wherein R is optionally substituted C1-7 alkyl, C5-20 aryl, or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl; or (iv) tetrazol-5-yl.
摘要翻译：式（I）化合物或其盐，溶剂合物和化学保护形式，其中R 2和R 5中的一个为：（i）H或任选地取代的C 1-4烷基; 或（ii）任选取代的C 5-7芳基; R 2和R 5中的另一个是另一个基团; m和n可以是0或1，m + n = 1或2 R N是H或任选取代的C 1-4烷基R 3， SUP>是：（i）羧基; （ii）式（II）的基团：（iii）式（III）的基团：其中R是任选取代的C 1-7烷基，C 5〜20 其中R 3，N 3和R 4各自独立地选自任选取代的C 1 -C 6芳基或NR N 3 N， 1-4个C 1-4烷基; 或（iv）四唑-5-基。

5. 发明申请

US20050124676A1 EP4 receptor antagonists 失效
标题翻译： EP4受体拮抗剂
公开(公告)号：US20050124676A1
公开(公告)日：2005-06-09
申请号：US10964831
申请日：2004-10-15
申请人： David Clark , Neil Harris , Garry Fenton , George Hynd , Keith Stuttle , Jonathan Sutton , Alexander Oxford , Richard Davis , Robert Coleman , Kenneth Clark
发明人： David Clark , Neil Harris , Garry Fenton , George Hynd , Keith Stuttle , Jonathan Sutton , Alexander Oxford , Richard Davis , Robert Coleman , Kenneth Clark
IPC分类号： A61K31/34 , A61K31/41 , C07D307/68 , C07D45/02
CPC分类号： C07D307/68
摘要： A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein one of R2 and R5 is: (i) H or an optionally substituted C1-4 alkyl group; or (ii)an optionally substituted C5-7 aryl; and the other of R2 and R5 is the other group; m and n can be 0 or 1, and m+n=1 or 2 RN is H or optionally substituted C1-4 alkyl R3 is either: (i) carboxy; (ii) a group of formula (II): (iii) a group of formula (III): wherein R is optionally substituted C1-7 alkyl, C5-20 aryl, or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl; or (iv) tetrazol-5-yl.
摘要翻译：式（I）化合物或其盐，溶剂合物和化学保护形式，其中R 2和R 5中的一个为：（i）H或任选地取代的C 1-4烷基; 或（ii）任选取代的C 5-7芳基; R 2和R 5中的另一个是另一个基团; m和n可以是0或1，m + n = 1或2 R N是H或任选取代的C 1-4烷基R 3， SUP>是：（i）羧基; （ii）式（II）的基团：（iii）式（III）的基团：其中R是任选取代的C 1-7烷基，C 5〜20 其中R 3，N 3和R 4各自独立地选自任选取代的C 1 -C 6芳基或NR N 3 N， 1-4个C 1-4烷基; 或（iv）四唑-5-基。

6. 外观设计

USD843001S1 Massage roller core 有权
公开(公告)号：USD843001S1
公开(公告)日：2019-03-12
申请号：US29558349
申请日：2016-03-16
申请人： Richard Davis , Charles Caswell
设计人： Richard Davis , Charles Caswell
摘要： FIG. 1 is a three-quarters perspective view thereof, with the massage surface or body of a massage roller reflected in dashed lines surrounding the core for illustrative purposes only as it is not a claimed feature of this invention;
FIG. 2 is a three-quarters perspective view thereof, showing only the massage roller core;
FIG. 3 is an end view thereof, with the massage surface or body of the massage roller reflected in dashed lines surrounding the core for illustrative purposes only as it is not a claimed feature of this invention, the opposite side being the mirror image; and,
FIG. 4 is a cross-section side view thereof taken at line 4-4 of FIG. 3 with the massage surface or body of the massage roller reflected in dashed lines surrounding the core for illustrative purposes only as it is not a claimed feature of this invention.
A massage roller core is disclosed. The core is referred to as an “X-core” and/or otherwise described as being “finned.”
The features of the massage roller core are shown and described in the drawings.

7. 发明授权

US09457048B2 Absorbent ingestible agents and associated methods of manufacture and use 有权
标题翻译：吸收性可摄取剂和相关的制造和使用方法
公开(公告)号：US09457048B2
公开(公告)日：2016-10-04
申请号：US12365447
申请日：2009-02-04
申请人： Richard Davis , Lior Sher
发明人： Richard Davis , Lior Sher
IPC分类号： A61K31/78 , A23L1/29 , A23L1/305 , A23L1/308 , A61K9/00 , A61K9/48 , A61K31/198 , A61K31/201 , A61K33/06 , A61K45/06
CPC分类号： A61K31/78 , A23L33/175 , A23L33/25 , A23L33/30 , A23V2002/00 , A61K9/0053 , A61K9/0056 , A61K9/0065 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K31/198 , A61K31/201 , A61K33/06 , A61K45/06 , A61K47/183 , C08F120/06 , C08F2810/20 , A61K2300/00
摘要： Appetite suppression and weight management achieved through pre-meal ingestion of temporary gastric bulking agents in the form of superabsorbent polymer hydrogels (SAPHs) selected from among a group consisting of crosslinked polycarboxylic acid moieties is described. The preferred compositions and manufacturing methods of ultrapure preparations of ingestible forms; as well as the preferred methods of use, dosage and administration; distribution and delivery of SAPH materials are also described.
摘要翻译：描述了通过膳食前摄入以选自交联多元羧酸部分的超吸收性聚合物水凝胶（SAPH）的形式的临时胃膨胀剂进行的食欲抑制和体重管理。优选的可摄取形式的超纯制剂的组合物和制造方法; 以及优选的使用方法，剂量和给药方法; 还描述了SAPH材料的分布和递送。

8. 发明申请

US20110306475A1 Exercise apparatus for permitting a user to build muscle strength in an ergonomic fashion 审中-公开
标题翻译：用于允许用户以人体工程学方式建立肌肉力量的运动装置
公开(公告)号：US20110306475A1
公开(公告)日：2011-12-15
申请号：US12813790
申请日：2010-06-11
申请人： Charles Caswell , Richard Davis
发明人： Charles Caswell , Richard Davis
IPC分类号： A63B21/06
CPC分类号： A63B21/072 , A63B21/0601 , A63B21/4035 , A63B21/4039
摘要： An exercise apparatus for permitting a user to build muscle strength in an ergonomic fashion comprising a weighted body with a first and second opposing faces with a handle attached to the body in a manner that permits the user to grip the apparatus during use without having to grip the body directly, and the first face comprises an ergonomic generally concave surface configured to more closely conform to the user's forearm profile when the apparatus is gripped by the user in a manner such that the body comes in contact with the user's forearm. Alternate embodiment incorporates a second face comprising an ergonomic generally concave surface.
摘要翻译：一种用于允许使用者以人体工程学方式建立肌肉力量的锻炼设备，包括具有第一和第二相对面的加重体，所述第一和第二相对面具有以允许使用者在使用过程中握住设备而不必握住的方式附接到身体的手柄并且所述第一面包括符合人体工程学的大体上凹形的表面，所述表面被构造成当所述装置以使得所述身体与所述使用者的前臂接触的方式被所述用户抓握时更接近于所述用户的前臂轮廓。替代实施例包括包含符合人体工程学的大体凹面的第二面。

9. 发明申请

US20110254735A1 SIGNAL PATH DELAY DETERMINATION 有权
公开(公告)号：US20110254735A1
公开(公告)日：2011-10-20
申请号：US13169992
申请日：2011-06-27
申请人： Richard Davis , Stalin Albanes
发明人： Richard Davis , Stalin Albanes
IPC分类号： G01S1/24
CPC分类号： H04W24/08 , H04W16/18 , H04W64/00
摘要： Propagation time for a target signal path is determined by detecting and processing a plurality of unknown signals received at two locations. A third location is established, such that the propagation time between the third location and one of the two locations is known, and the signal path between the third location and the other of the two locations is the target signal path. The two locations are monitored for any signals that may be detected. Signals received at the two locations are processed to determine which signals have a common source, and of the signals having a common source, the signal having the greatest delay between times of reception at the two locations is selected. The selected signal is used to determine the propagation time between the two locations.

10. 外观设计

USD633156S1 Combined chin up and exercise bar 有权
标题翻译：组合下巴和运动酒吧
公开(公告)号：USD633156S1
公开(公告)日：2011-02-22
申请号：US29352623
申请日：2009-12-23
申请人： Charles Caswell , Richard Davis
设计人： Charles Caswell , Richard Davis

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式